ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has announced a major evolution of its research & development activities with the design of CRISPRChek, a new line of molecular assays using the disruptive CRISPR technology.
The company is investing in a technology with the potential to achieve ultra-high sensitivity, enhanced-multiplexing capacity, and the ability to operate with various detection systems. ABL Diagnostics is working to develop kits able to compete with the currently adopted methods for DNA or RNA detection or quantification.
The first prototypes to be developed are targeting HIV-1 and SARS-CoV-2. Dr. Sofiane Mohamed, Head of Research and Development, expressed confidence that the team of experts will face the “exciting challenges which will finally lead to innovative assays with the potential to revolution the way molecular detection is currently carried-out by all laboratories worldwide.”
ABL Diagnostics is also developing genotyping-through-sequencing tests (DeepChek®) and molecular biology products for clinical specimen collection (MediaChek®). The company offers an Electronic Medical Record (EMR) system called Nadis®, which is CE-marked and used in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.
ABL Diagnostics, based in Woippy, France, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
Today, ABL Diagnostics announced the launch of CRISPRChek, a new line of PCR detection assays using the disruptive CRISPR technology. The company is investing in a technology with the potential to achieve ultra-high sensitivity, enhanced-multiplexing capacity, and the ability to operate with various detection systems. The first prototypes will target HIV-1 and SARS-CoV-2.
Dr. Sofiane Mohamed, Head of Research and Development, said “I’m confident that our team of experts will face these exciting challenges which will finally lead to innovative assays with the potential to revolution the way molecular detection is currently carried-out by all laboratories worldwide.”
ABL Diagnostics is also developing genotyping-through-sequencing tests (DeepChek®) and molecular biology products for clinical specimen collection (MediaChek®). The company offers an Electronic Medical Record (EMR) system called Nadis®, which is CE-marked and used in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.
ABL Diagnostics, based in Woippy, France, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
Today, ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, announced the launch of CRISPRChek, a new line of PCR detection assays using the disruptive CRISPR technology.
The company is investing in a technology with the potential to achieve ultra-high sensitivity, enhanced-multiplexing capacity, and the ability to operate with various detection systems. The first prototypes are targeting HIV-1 and SARS-CoV-2.
Dr. Sofiane Mohamed, Head of Research and Development, expressed confidence that the team of experts will face the “exciting challenges which will finally lead to innovative assays with the potential to revolution the way molecular detection is currently carried-out by all laboratories worldwide.”
ABL Diagnostics is also developing genotyping-through-sequencing tests (DeepChek®) and molecular biology products for clinical specimen collection (MediaChek®). The company offers an Electronic Medical Record (EMR) system called Nadis®, which is CE-marked and used in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.
Based in Woippy, France, ABL Diagnostics is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
Today, ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, announced a major evolution of its research & development activities with the launch of CRISPRChek, a new line of PCR detection assays using the disruptive CRISPR technology.
The company is investing in a technology with the potential to achieve ultra-high sensitivity, enhanced-multiplexing capacity
